Uptake of hepatitis C direct-acting antiviral treatment in China: a retrospective study from 2017 to 2021

ConclusionsCentral negotiations to reduce prices of DAAs resulted in inclusion of DAA treatment under the universal health insurance, which are critical elements that support scaling up access to hepatitis C treatment in China. However, the current treatment rates are still far below the global target. Targeting the PLADs lagged behind through raising public awareness, strengthening capacity of the healthcare providers by roving training, and integrate prevention, screening, diagnosis, treatment and follow-up management of hepatitis C into the existing services are needed.
Source: Infectious Diseases of Poverty - Category: Infectious Diseases Source Type: research